Match!
Arya Amini
City of Hope National Medical Center
173Publications
17H-index
840Citations
Publications 173
Newest
#1Arya Amini (City of Hope National Medical Center)H-Index: 17
#2Vivek Verma (Allegheny General Hospital)H-Index: 15
Last.S.M. Glaser (City of Hope National Medical Center)H-Index: 1
view all 11 authors...
Source
Source
#1Amanda F. Saltzman (UK: University of Kentucky)H-Index: 4
#2Alonso Carrasco (Boston Children's Hospital)H-Index: 3
Last.Nicholas G. Cost (CU: University of Colorado Boulder)H-Index: 19
view all 4 authors...
Abstract Objective To describe and compare the management of WT and oncologic outcomes by patient age using a large national database. Methods The National Cancer Database was queried for patients with WT diagnosis from 2004-2013. Patients were grouped by age and compared: pediatric ( 35 years). Overall survival (OS) was the primary endpoint. Factors associated with OS were determined using multivariate analysis. Results The majority of patients were pediatric (n=2,686), followed by young adult ...
Source
Source
#1Dawei Chen (SDU: Shandong University)
#2Hari Menon (University of Texas MD Anderson Cancer Center)H-Index: 3
Last.James Welsh (University of Texas MD Anderson Cancer Center)H-Index: 34
view all 20 authors...
Importance Effective treatment options for locally advanced esophageal cancer are limited, and rates of local recurrence after standard chemoradiotherapy remain high. Objective To evaluate toxic effects, local control, and overall survival rates after chemoradiotherapy with a simultaneous integrated boost of radiotherapy dose to the gross tumor and nodal disease for patients with unresectable locally advanced esophageal cancer. Design, Setting, and Participants A phase 1/2, single-arm trial was ...
Source
The oncologic importance of an epidermal growth factor receptor (EGFR) mutation in the era of tyrosine-kinase inhibitors (TKIs) for patients with metastatic non-small cell lung cancer (NSCLC) cannot be overstated. The multiple positive trials evaluating gefitinib, erlotinib, and more recently osimeritinib as first line treatment of EGFR mutated NSCLC have revolutionized NSCLC management, with significantly improved oncologic and toxicity outcomes in this subset of patients (1-3).
Source
Source
Source
Source
Source
12345678910